Figure 1

Profile of the study cohort. ART = Antiretroviral therapy; AZT = Zidovudine; D4T = Stavudine; EFV = efavirenz; NVP = Nevirapine; OBRs = optimized background regimens; TDF = tenofovir; 3TC = lamivudine. ^aRandom sampling was performed using random numbers. ^bHIV-1-infected patients who simultaneously discontinued all drugs in NVP-based regimens when they experienced allergic reactions to NVP-based regimens. ^cHIV-1-infected patients who discontinued NVP first but continued use of the other NRTIs for a few days when they experienced allergic reactions to NVP-based regimens. ^dThis criterion included patients who changed EFV to other NNRTIs or PIs. It did not include patients who only changed or modify NRTIs. ^eVirological failure was defined as either (1) having two consecutive results of plasma HIV-1 RNA >400 copies/ml after 6 month of a EFV-based regimen or (2) having plasma HIV-1 RNA >1,000 copies/ml plus having any genotypic resistance mutation to efavirenz-based regimen. ^fIt included either (1) patients who did not have clinical visits for more than 3 months from appointment date or (2) patients who stopped efavirenz-based regimen for more than 3 months. ^gThe cohort ended on 31 March 2010.